A Phase III, Multicenter Study of the Efficacy and Safety of Adalimumab Treatment in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Next Previous
Trial Profile

A Phase III, Multicenter Study of the Efficacy and Safety of Adalimumab Treatment in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jan 2018

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Acronyms REVEAL
  • Sponsors Abbott GmbH & Co. KG

    • Most Recent Events

    • 01 Jan 2018 Results comparing Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis in patients data from M10-114, M10-315, REVEAL and CHAMPION trials (n=1692), published in the Value in Health
    • 05 Nov 2016 Results of a post-hoc analysis assessing efficacy of adalimumab by body region and regional response and quality of life relationship, published in the American Journal of Clinical Dermatology
    • 07 Jul 2016 According to an Abbvie media release, data from this trial will be presented at Psoriasis 2016 - 5th Congress of the Psoriasis International Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top